Chittoria Konica, Sharma Ankur, Kothari Nikhil, Kumari Kamlesh
Department of Anesthesiology and Critical Care, AIIMS, Jodhpur, Rajasthan, India.
Department of Trauma and Emergency (Anesthesiology and Critical Care), AIIMS, Jodhpur, Rajasthan, India.
Saudi J Anaesth. 2025 Jul-Sep;19(3):384-386. doi: 10.4103/sja.sja_366_25. Epub 2025 Jun 16.
Suzetrigine is the first and only FDA-approved non-opioid oral medication designed to be used for the treatment of moderate-to-severe acute pain. It represents a significant step forward in pain treatment by providing excellent relief without the hazards associated with opiate usage. Its approval transforms postoperative pain care, meeting a key public health need while lowering addiction concerns. While the adverse effect profile requires additional investigation, its distinctive mechanism and safety feature represent a game-changing potential in the area of analgesia.
舒泽曲辛是首个也是唯一获美国食品药品监督管理局批准的非阿片类口服药物，用于治疗中重度急性疼痛。它在疼痛治疗方面迈出了重要一步，能提供出色的疼痛缓解效果，且没有与使用阿片类药物相关的风险。它的获批改变了术后疼痛护理，满足了一项关键的公共卫生需求，同时降低了成瘾方面的担忧。虽然其不良反应情况还需要进一步研究，但它独特的作用机制和安全特性在镇痛领域具有改变游戏规则的潜力。
